Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target

Structure Therapeutics (GPCR) reported highly positive Phase 2 ACCESS II data for aleniglipron, achieving ~16% placebo-adjusted weight loss with strong statistical significance and no plateau. Aleniglipron's oral, non-peptide, once-daily profile with injectable-level efficacy and improved tolerability positions GPCR as a potential best-in-class oral GLP-1 therapy. GPCR's $1.4B cash position funds operations into 2028, supporting Phase 3 development and pipeline expansion without immediate dilution risk.